Abstract:Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. It is estimated that 13,410 cases will be diagnosed and 8,990 will die of AML in the United States in 2007 (http://seer.cancer.gov). AML is a genetically diverse hematopoietic malignancy with variable response to treatment. Expression profiling of protein-coding genes using DNA microarray in AML has resulted in inconsistent data from different laboratories. Therefore, further validation of these observations in large cohorts and in independent studies is definitely required before clinical application becomes feasible. Recently, Golub and colleagues described a new, bead-based flow cytometric microRNA (miRNAs, miRs) expression profiling method that could successfully classify tumors. MiRNAs are endogenous ∼22 nucleotide non-coding RNAs, which can function as oncogenes and tumor suppressors. To provide new insights into the complex genetic alterations in leukemogenesis and to identify novel markers for diagnosis and treatment of AML, we performed a genome-wide analysis of miRNA expression profiles using the bead-based method on 54 AML samples with common translocations including t(15;17), t(8;21), inv(16), and 11q23 rearrangement, along with normal controls. In both unsupervised and supervised hierarchical cluster analyses, we observed that t(15;17) samples grouped together as one cluster, as do the 11q23 rearrangement samples. Interestingly, t(8;21) and inv(16), both CBF (core-binding factor) AMLs, grouped together as a unique cluster. Forty-one miRNAs exhibited significantly differential expression between different subtypes of AMLs, and/or between AMLs and normal controls. Notably, expression signature of a minimal number of two, three, and seven miRNAs could be used for class prediction of CBF, t(15;17), and 11q23 rearrangement AMLs, respectively, with an overall diagnostic accuracy of 94–96%. We further showed that overexpression of the two discriminatory miRNAs in CBF AML is associated with epigenetic regulation, rather than DNA copy number amplification. Moreover, several important target genes of these discriminatory miRNAs have also been validated. We are currently exploring the role of these discriminatory miRNAs and their critical target genes in the development of AML using in vitro and in vivo models. This work will enhance our understanding of the biological role of these miRNAs and their targets in leukemogenesis.

Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia

MiR-362-5p As a Novel Prognostic Predictor of Cytogenetically Normal Acute Myeloid Leukemia

A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Profiling of Micrornas in Aml Cells Following Overexpression or Silencing of the Vegf Gene

High Expression of Mir-363 Predicts Poor Prognosis and Guides Treatment Selection in Acute Myeloid Leukemia

Circulating Plasma Exosomal Long Non-Coding RNAs LINC00265, LINC00467, UCA1, and SNHG1 As Biomarkers for Diagnosis and Treatment Monitoring of Acute Myeloid Leukemia.

MiR-425 Expression Profiling in Acute Myeloid Leukemia Might Guide the Treatment Choice Between Allogeneic Transplantation and Chemotherapy

A three‑lncRNA signature for prognosis prediction of acute myeloid leukemia in patients.

Use of extracellular vesicle microRNA profiles in patients with acute myeloid leukemia for the identification of novel biomarkers

Elevated Serum Exosomal Mir-125B Level As a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia.

A Novel Immune-Related Competing Endogenous RNA Network Predicts Prognosis of Acute Myeloid Leukemia

High Expression of Microrna-500 is Associated with Poor Prognosis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.

Construction of an Immune-Related Prognostic Signature and lncRNA‒miRNA–mRNA ceRNA Network in Acute Myeloid Leukaemia

Novel Prognostic Genes and Subclasses of Acute Myeloid Leukemia Revealed by Survival Analysis of Gene Expression Data.

Gene coexpression network analysis revealed biomarkers correlated with blast cells and survival in acute myeloid leukemia

MicroRNA-181a-3p As a Diagnostic and Prognostic Biomarker for Acute Myeloid Leukemia.

MicroRNAs of bone marrow mesenchymal stem cell-derived exosomes regulate acute myeloid leukemia cell proliferation and apoptosis

LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia

SLC25A1-associated prognostic signature predicts poor survival in acute myeloid leukemia patients

Integration of CD34 + CD117 Dim Population Signature Improves the Prognosis Prediction of Acute Myeloid Leukemia